Phosphoinositide 3-Kinase Inhibitor Compounds and Methods of Use
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 60/873,448, filed Dec 7, 2006. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,383,620 | Phosphoinositide 3-Kinase Inhibitor Compounds and Methods of Use In force · High confidence | F. Hoffmann-La Roche AG | In force | High confidence | ||
| US 8,993,563 | Phosphoinositide 3-Kinase Inhibitor Compounds and Methods of Use In force · High confidence | Genentech, Inc. and F. Hoffmann-La Roche AG | In force | High confidence | ||
| US 7,888,352 | Phosphoinositide 3-Kinase Inhibitor Compounds and Methods of Use In force · High confidence | F. Hoffmann-La Roche AG | In force | High confidence |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.